Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tiotropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 17/20 | 0.96 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.96 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.94 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.94 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.94 |
| ▸ | TSPO | P30536 | 1/20 | 0.94 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.94 |
| ▸ | HRH1 | P35367 | 1/20 | 0.94 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.94 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.94 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.94 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiotropium SCHEMBL1260638 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL27726355 | 0.99 | CHRM3 (0.96) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL2231780 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL433959 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL2231775 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL155761 | 0.98 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL14672487 | 0.98 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL4589 | 0.98 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL21483687 | 0.98 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL19581677 | 0.98 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3414243-A1 | CRYSTALLINE FORM OF TIOTROPIUM BROMIDE ANHYDRATE | Sima Patent Ve Lisanslama Hizmetleri Ltd. STI (TR) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017138896-A1 | CRYSTALLINE FORM OF TIOTROPIUM BROMIDE ANHYDRATE | SIMA PATENT VE LISANSLAMA HIZMETLERI LTD. ŞTI (TR) | 2017-08-17 | — | — | WO | disclosed |
| EP-3030224-A1 | INHALABLE PARTICLES COMPRISING TIOTROPIUM AND INDACATEROL | Chemo Research, S.L. (ES) | 2016-06-15 | — | — | EP | disclosed |
| US-9090607-B2 | Process for preparing tiotropium bromide | HOVIONE INTERNATIONAL LIMITED (CN) | 2015-07-28 | — | — | US | disclosed |
| WO-2015018800-A1 | INHALABLE PARTICLES COMPRISING TIOTROPIUM AND INDACATEROL | CHEMO RESEARCH, S.L. (ES) | 2015-02-12 | — | — | WO | disclosed |
| CN-101166738-B | Novel crystalline forms of tiotropium bromide | BOEHRINGER INGELHEIM INT | 2011-06-01 | — | — | CN | disclosed |
| US-7879871-B2 | crystalline anisol solvate of tiotropium bromide characterized by an X-ray powder diffraction pattern with a characteristic value d=4.14 A; for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| EP-2085396-A2 | Novel crystalline forms of tiotropium bromide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-05 | — | — | EP | disclosed |
| CN-101203513-A | Crystalline forms of tiotropium bromide | BOEHRINGER INGELHEIM INT (DE) | 2008-06-18 | — | — | CN | disclosed |
| CN-101166738-A | Novel crystalline forms of tiotropium bromide | BOEHRINGER INGELHEIM INT (DE) | 2008-04-23 | — | — | CN | disclosed |
| EP-1881980-A2 | NOVEL CRYSTALLINE FORMS OF TIOTROPIUM BROMIDE | Boehringer Ingelheim International GmbH (DE) | 2008-01-30 | — | — | EP | disclosed |
| US-20070092453-A1 | Novel Crystalline Forms of Tiotropium Bromide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| WO-2006117299-A9 | NOVEL CRYSTALLINE FORMS OF TIOTROPIUM BROMIDE | BOEHRINGER INGELHEIM INT (DE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006117299-A2 | NOVEL CRYSTALLINE FORMS OF TIOTROPIUM BROMIDE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070092453-A1 | Novel Crystalline Forms of Tiotropium Bromide | CHRM3, CHRM2, CHRNB1 | CHRM3 1/4885CHRM2 2/4885CHRM1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.